Table 2.

Comparison between modeling group and validation group by clinicopathological characteristics.

Variable	N	Modeling		Validation		P-value
		population	%	population	%
No. of cases	633	500		133
Age						0.892
<40	52	42	80.80	10	18.20
40–70	547	432	79.00	115	21.00
>70	34	26	76.50	8	5.40
Tumor location						0.178
UOQ	313	241	77.00	72	23.00
LOQ	47	42	89.40	5	10.60
UIQ	127	96	75.60	31	24.40
LIQ	42	36	85.70	6	4.30
Central	104	85	81.70	19	18.30
Tumor type						0.439
Ductal	609	483	79.3	126	20.70
Lobular	10	6	60.00	4	40.00
Mixed	10	7	70.00	3	30.00
Mucinous	3	3	100.00	0	0.00
Medullary	1	1	100.00	0	0.00
Clinical stage						0.270
I	191	157	82.20	34	17.80
II	440	342	77.70	98	22.30
III	2	1	50.00	1	50.00
Pathological grade						0.899
1	17	13	76.50	4	23.50
2	582	461	79.20	161	20.80
3	34	26	76.50	8	23.50
ER						0.353
Present	481	384	79.80	97	20.20
Absent	152	116	76.30	36	23.70
PR						0.234
Present	427	343	80.30	84	19.70
Absent	206	157	76.20	49	23.80
HER2						0.802
Present	88	71	80.70	17	19.30
Absent	545	427	78.80	115	21.20
Ki67						0.960
Present	392	148	37.76	244	62.24
Absent	241	79	32.78	162	67.22
Breast gland content						0.769
<25%	99	82	82.80	17	17.20
26–50%	184	144	78.30	40	21.70
51–75%	305	238	78.00	67	22.00
>75%	45	36	80.00	9	20.00
Tumor morphology						0.056
Lump	378	311	82.33	67	17.70
Mass with calcification	96	70	72.90	26	27.10
No mass	159	119	74.80	40	25.20
SLN						0.073
Present	227	170	74.90	57	24.10
Absent	406	330	81.30	76	18.70